Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for PDGFRA D842V-mutant GIST, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No proven therapy after progression on avapritinib.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Cognitive side effects limit dose and quality of life for some patients.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Whether indolent D842V tumours can be watched rather than resected.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
PFS HR 1.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.